Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada has approved Cangene Corporation's liquid formulation of WinRho SDF to treat hemolytic disease of the newborn and a bleeding disorder called immune thrombocytopenic purpura. It can also be used to treat certain transfusion reactions.
Subscribe to our email newsletter
The company said that WinRho SDF (Rho(D) Immune Globulin (Human)) liquid provides a convenient alternative to the lyophilized (freeze-dried) version of the therapeutic by eliminating the need for reconstitution of the product prior to administration.
John Langstaff, Cangene’s president and CEO, said: “Ease of administration can be an important feature for a drug, and liquid formulations offer increased convenience to physicians. This convenient formulation of WinRho SDF has been available since 2006 in the US and we are pleased to be able to provide it to physicians in Canada.”